Evidence Planner

Before a new drug reaches the market, it has to go through several registering, licensing, and approval procedures with drug regulators, such as the FDA in the US, and the EMA in the EU. 

There are different licensing and approval paths and methods that pharmaceutical companies can follow. No matter the path, these procedures are expensive, time-consuming, and risky. A pharmaceutical company may spend several years and millions of dollars, only to realize that the chosen method and licensing path has delayed or prevented the licensing party (e.g. the FDA) from approving the drug.

IQVIA developed the idea for an application, dubbed “Evidence Planner,” that would allow pharmaceutical companies to model different licensing methods and paths in advance, and forecast the success factor of each of these methods. Pharmaceutical companies could then make a decision based on these methods. 

IQVIA partnered with Proxet to build a minimum viable product (MVP) version of Evidence Planner, and to integrate the planner into e360, IQVIA’s existing branded infrastructure. Evidence Planner allows pharmaceutical companies to enter all of their data related to probable licensing methods and uses artificial intelligence to generate estimates of how long this method will take, how much money will be spent, and the probability of this method succeeds.

The project scope included:

  1. Designing the entire application UI interface.
  2. Designing the infrastructure and integrations with other services and parties.
  3. Designing and implementing the database.
  4. Designing and implementing the backend services and APIs.
  5. Designing and implementing a frontend application.
  6. Integrating Machine learning models and algorithms.
  7. Integrating Evidence Planner application with IQVIA’s e360 infrastructure.


  • ReactJS
  • TypeScript
  • .NET Core
  • MS SQL Server
  • Docker
  • Kubernetes
Evidence Planner

Stand with Ukraine

We stand with our friends and colleagues during this struggle for their freedom and independence—and lives, above all. To support Ukraine in its direst hours, visit this page.